Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors

J Clin Oncol. 2017 Jan 10;35(2):131-134. doi: 10.1200/JCO.2016.70.5061. Epub 2016 Dec 5.

Authors

Alison M Schram¹, Martin H Voss¹, David M Hyman¹

Affiliation

¹ Alison M. Schram, Memorial Sloan Kettering Cancer Center; and Martin H. Voss and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.

PMID: 27918716
DOI: 10.1200/JCO.2016.70.5061

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Neoplasms*
Phenylurea Compounds
Pyrimidines
Receptor, Fibroblast Growth Factor, Type 1
Receptors, Fibroblast Growth Factor*

Substances

Phenylurea Compounds
Pyrimidines
Receptors, Fibroblast Growth Factor
infigratinib
Receptor, Fibroblast Growth Factor, Type 1

Grants and funding